Dihydrotestosterone (DHT)

Dihydrotestosterone and dihydrotestosterone/ratio may be used for differential diagnosis of diseases of sexual differentiation (DSD). DHT levels may be inappropriately low compared to testosterone levels in 5a-reductase deficiency. It is recommended by guidelines to measure the ratio of testosterone to DHT.

DHT levels may also be monitored to follow the effectiveness of 5a-reductase inhibitor treatment in female alopecia.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

Douglas G, Axelrad ME, Brandt ML, et.al. Guidelines for Evaluating and Managing Children Born with Disorders of Sexual Development. Pediatr Ann. 2012 Apr:41(4):e1-e7. PubMed 22494213

Goodman NF, Cobin RH, Futterweit W, et. al. Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome--Part 1. Endocr Pract. 2015 Nov;21(11):1291-1300. PubMed 26509855

Hughes IA, Houk C, Ahmed SF, Lee PA; LWPES Consensus Group; ESPE Consensus Group. Consensus statement on management of intersex disorders. Arch Dis Child. 2006 Jul;91(7):554-563. PubMed 16624884

Ocal G. Current Concepts in Disorders of Sexual Development. J Clin Res Pediatr Endocrinol. 2011;3(3):105-114. PubMed 21911322